Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
- Conditions
- Thyroid Eye Disease
- Interventions
- Other: Observational cohort study
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 180
- Registration Number
- NCT05517447
- Locations
- πΊπΈ
Site Number - 1508, Houston, Texas, United States
π¬πͺSite Number - 3455, Tbilisi, Georgia
π¬πͺSite Number - 3451, Tbilisi, Georgia
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT05517421
- Locations
- πΊπΈ
Site Number - 1557, Beverly Hills, California, United States
πΊπΈSite Number - 1539, Carlsbad, California, United States
πΊπΈSite Number - 1502, Los Angeles, California, United States
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 240
- Registration Number
- NCT05403541
- Locations
- πΊπΈ
Site Number -1022, Phoenix, Arizona, United States
πΊπΈSite Number -1029, Scottsdale, Arizona, United States
πΊπΈSite Number -1002, Carlsbad, California, United States
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Interventions
- Drug: RVT-1401 680 mg/weeklyDrug: RVT-1401 340 mg/weekly
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 5
- Registration Number
- NCT04253236
- Locations
- πΊπΈ
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
πΊπΈNorton Cancer Institute, Louisville, Kentucky, United States
πΊπΈMassachusetts General Hospital Cancer Center - Hematology/Oncology, Boston, Massachusetts, United States
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
- Conditions
- Graves' Ophthalmopathy (GO)
- Interventions
- Other: Placebo (Administered via subcutaneous injection)Drug: RVT-1401 (Administered via subcutaneous injection)
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 65
- Registration Number
- NCT03938545
- Locations
- πΊπΈ
Multispecialty Aesthetic Clinical Research Organziation (MACRO), Beverly Hills, California, United States
πΊπΈDoheny Eye Center UCLA, Pasadena, California, United States
πΊπΈUniversity of Miami Miller School of Medicine Bascom Palmer Eye Institute, Miami, Florida, United States
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 7
- Registration Number
- NCT03922321
- Locations
- π¨π¦
UBC/VGH Eye Care Center, Vancouver, British Columbia, Canada
π¨π¦Toronto Retina Institute, North York, Ontario, Canada
π¨π¦University of Ottwa Eye Institute, Ottawa, Ontario, Canada
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 17
- Registration Number
- NCT03863080
- Locations
- πΊπΈ
IMC/Diagnostic and Medical Clinic, Mobile, Alabama, United States
πΊπΈPhoenix Neurological Associates, Phoenix, Arizona, United States
πΊπΈThe Neurology Center of Southern California, Carlsbad, California, United States